Literature DB >> 17088366

Genotyping of varicella-zoster virus and the discrimination of Oka vaccine strains by TaqMan real-time PCR.

S P Parker1, M Quinlivan, Y Taha, J Breuer.   

Abstract

Single nucleotide polymorphisms (SNPs) in five genes have been used to identify four major subtypes of wild-type varicella-zoster virus (VZV) A, B, C, and J. Additional SNPs, located in the IE62 major transactivating gene can be used to differentiate the Oka vaccine strain (vOka) from wild-type VZV. Primer-probe sets for the detection of the five polymorphic loci were designed by Applied Biosystems for the ABI 7900HT platform. Probes for each allele were labeled with VIC or 6-carboxyfluorescein fluorogenic markers. Each primer-probe set was validated to establish assay sensitivity and specificity using VZV DNA of predetermined copy number and genotype. Further evaluation was carried out using DNA samples from the vesicle fluid or skin swab of the rash of adult patients with herpes zoster or rashes due to vOka. Assay sensitivity ranged from 10 and 10(8) copies/ml of VZV DNA (equivalent to 2 to 20 copies per reaction). Statistical analyses showed that for each genotype, a set of two probes clearly differentiated the nucleotide present (allele) at that locus (P < 0.0001). It was possible to determine the genotype of wild-type VZV using one of four SNP assays and also to differentiate wild type from vOka using a single SNP assay. The assay can be used for diagnostic and epidemiological studies of VZV, including the differentiation of vOka from wild-type strains, investigation of breakthrough infections, and varicella outbreaks following immunization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088366      PMCID: PMC1698295          DOI: 10.1128/JCM.00346-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Phylogenetic analysis of varicella-zoster virus: evidence of intercontinental spread of genotypes and recombination.

Authors:  Winsome Barrett Muir; Richard Nichols; Judith Breuer
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 2.  Identification and mapping of single nucleotide polymorphisms in the varicella-zoster virus genome.

Authors:  B Faga; W Maury; D A Bruckner; C Grose
Journal:  Virology       Date:  2001-02-01       Impact factor: 3.616

Review 3.  Quantification using real-time PCR technology: applications and limitations.

Authors:  Dieter Klein
Journal:  Trends Mol Med       Date:  2002-06       Impact factor: 11.951

4.  An elementary school outbreak of varicella attributed to vaccine failure: policy implications.

Authors:  Brian R Lee; Shelly L Feaver; Claudia A Miller; Craig W Hedberg; Kristen R Ehresmann
Journal:  J Infect Dis       Date:  2004-06-29       Impact factor: 5.226

5.  Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity.

Authors:  Y Gomi; T Imagawa; M Takahashi; K Yamanishi
Journal:  J Med Virol       Date:  2000-08       Impact factor: 2.327

6.  The postmarketing safety profile of varicella vaccine.

Authors:  R G Sharrar; P LaRussa; S A Galea; S P Steinberg; A R Sweet; R M Keatley; M E Wells; W P Stephenson; A A Gershon
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

7.  A real-time PCR assay for the detection of varicella-zoster virus DNA and differentiation of vaccine, wild-type and control strains.

Authors:  Graham A Tipples; David Safronetz; Michael Gray
Journal:  J Virol Methods       Date:  2003-11       Impact factor: 2.014

8.  Detection and genotyping of varicella-zoster virus by TaqMan allelic discrimination real-time PCR.

Authors:  Paul A Campsall; Nicholas H C Au; Julie S Prendiville; David P Speert; Rusung Tan; Eva E Thomas
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  The out of Africa model of varicella-zoster virus evolution: single nucleotide polymorphisms and private alleles distinguish Asian clades from European/North American clades.

Authors:  Timothy R Wagenaar; Vincent T K Chow; Chantanee Buranathai; Pranee Thawatsupha; Charles Grose
Journal:  Vaccine       Date:  2003-03-07       Impact factor: 3.641

10.  An evaluation of single nucleotide polymorphisms used to differentiate vaccine and wild type strains of varicella-zoster virus.

Authors:  Mark Quinlivan; Anne A Gershon; Sharon P Steinberg; Judith Breuer
Journal:  J Med Virol       Date:  2005-01       Impact factor: 2.327

View more
  14 in total

1.  VZV meningitis following varicella vaccine.

Authors:  Dahlene Fusco; Peter Krawitz; Philip LaRussa; Sharon Steinberg; Anne Gershon; Jonathan Jacobs
Journal:  J Clin Virol       Date:  2010-06-12       Impact factor: 3.168

2.  Arm Paralysis After Routine Childhood Vaccinations: Application of Advanced Molecular Methods to the Causality Assessment of an Adverse Event After Immunization.

Authors:  Jana Shaw; Neal A Halsey; Adriana Weinberg; D Scott Schmid; Kirsten St George; William C Weldon; Michael Jordan; Patrick W Bryant; Philip S LaRussa; Deborah Y Bradshaw; Theresa Harrington; Anne Gershon
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

3.  Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation.

Authors:  Preeti Bhalla; Graeme N Forrest; Michael Gershon; Yan Zhou; Jason Chen; Philip LaRussa; Sharon Steinberg; Anne A Gershon
Journal:  Clin Infect Dis       Date:  2014-12-01       Impact factor: 9.079

4.  Varicella zoster virus latency.

Authors:  Emily Eshleman; Aamir Shahzad; Randall J Cohrs
Journal:  Future Virol       Date:  2011-03       Impact factor: 1.831

5.  Use of Saliva to Identify Varicella Zoster Virus Infection of the Gut.

Authors:  Anne A Gershon; Jason Chen; Michael D Gershon
Journal:  Clin Infect Dis       Date:  2015-04-16       Impact factor: 9.079

Review 6.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

7.  Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand.

Authors:  Vladimir N Loparev; Elena N Rubtcova; Vanda Bostik; Dhwani Govil; Christopher J Birch; Julian D Druce; D Scott Schmid; Margaret C Croxson
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

Review 8.  Impact of varicella vaccine on varicella-zoster virus dynamics.

Authors:  D Scott Schmid; Aisha O Jumaan
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

9.  Discriminating between varicella-zoster virus vaccine and wild-type strains by loop-mediated isothermal amplification.

Authors:  Yuki Higashimoto; Masaru Ihira; Akane Ohta; Shigeki Inoue; Chie Usui; Yoshizo Asano; Tetsushi Yoshikawa
Journal:  J Clin Microbiol       Date:  2008-06-11       Impact factor: 5.948

10.  Vaccine Strain and Wild-Type Clades of Varicella-Zoster Virus in Central Nervous System and Non-CNS Disease, New York State, 2004-2019.

Authors:  Patrick Bryant; Tugba Yildirim; Sara B Griesemer; Kara Shaw; Dylan Ehrbar; Kirsten St George
Journal:  J Clin Microbiol       Date:  2022-03-24       Impact factor: 11.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.